Further characterization of the FASN-centered relationship between PRs, prolactin/PRLR/JAK/STAT5, and PI3K/AKT pathways will be required to determine whether therapeutic approaches directed at blocking the interaction between these pathways would be more beneficial to therapeutically manage prolactin and/or FASN signaling in breast cancer cells. Here, PRLR is linked to breast carcinoma.